Brandon Hill, MD
Adult Medicine · Jacksonville, FLNPI 1801155015
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 136 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AstraZeneca at 39.2% of the total.
Across 136 payments — averaging $21.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$310
- Exact Sciences$180
- AbbVie$156
- Dexcom, Inc.$138
- Boehringer Ingelheim$130
- plus $831 from 19 others
What the payments were for
- Food & beverage$2,869100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 35 | $1,125 |
| Novo Nordisk | 22 | $310 |
| Exact Sciences | 9 | $180 |
| AbbVie | 9 | $156 |
| Dexcom, Inc. | 7 | $138 |
| Boehringer Ingelheim | 7 | $130 |
| Pfizer | 6 | $117 |
| Xeris Pharmaceuticals, Inc. | 6 | $101 |
| Johnson & Johnson | 4 | $68 |
| GSK | 4 | $68 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $60 |
| Amgen | 4 | $57 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $46 |
| Corcept Therapeutics | 2 | $45 |
| Lilly USA, LLC | 3 | $43 |
| Abbott | 2 | $43 |
| Edwards Lifesciences | 2 | $38 |
| Mylan Specialty L.p. | 1 | $23 |
| Pulmonx Corporation | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $16 |
| Bayer | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,869 in reported general payments places this provider in the 85th percentile of 195 adult medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 111 | $161,665 |
| JardianceEmpagliflozin | 86 | $136,210 |
| EliquisApixaban | 50 | $62,069 |
| FarxigaDapagliflozin Propanediol | 42 | $51,493 |
| TrulicityDulaglutide | 20 | $38,684 |
| RybelsusSemaglutide | 11 | $23,470 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $20,685 |
| XareltoRivaroxaban | 11 | $15,918 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $14,130 |
| JanuviaSitagliptin Phosphate | 14 | $12,400 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 63 | $8,977 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 18 | $8,623 |
| Gabapentin | 309 | $4,545 |
| Testosterone | 11 | $3,871 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 166 | $3,614 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $310 | $185,134122 claims |
| Boehringer IngelheimJardiance | $130 | $136,21086 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,125 | $65,62365 claims |
| PfizerEliquis | $117 | $62,06950 claims |
| Lilly USA, LLCTrulicity | $43 | $38,68420 claims |
| GSKTrelegy Ellipta | $68 | $20,68532 claims |
| Johnson & JohnsonXarelto | $68 | $15,91811 claims |
| AbbVieSynthroid | $156 | $1,87239 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 195 adult medicine providers in Florida.
Other adult medicine in Jacksonville
- Juliana LlanoJacksonville$5K
- Jimmy DouradoJacksonville$1K
- Steven SantiagoMiami$290K
- Tammy DsouzaKissimmee$191K
- Eric SchertzerPlantation$26K
- Ricardo SerranoMerritt Island$20K
- Marlene JarinMiami Beach$18K
- Myra ReedPanama City Beach$16K
- Joshua RycusCoral Springs$13K
- Frederick WeigandDeltona$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.